8 Mar, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

alzheon2024-08-12T09:23:49-04:00March 8th, 2022|

Read More

8 Feb, 2022

Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

alzheon2024-08-12T09:05:12-04:00February 8th, 2022|

Read More

5 Jan, 2022

Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022

alzheon2024-08-12T09:33:43-04:00January 5th, 2022|

Read More

1 Jan, 2022

Anti-Amyloid Drugs: The Failure Of Success

alzheon2022-01-04T13:37:06-05:00January 1st, 2022|

Read More

9 Nov, 2021

Big Pharma Abandoned Alzheimer’s, This Good Unicorn Stayed And Found A Potential Cure

alzheon2021-11-09T18:42:03-05:00November 9th, 2021|

Read More

1 Nov, 2021

Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

alzheon2024-08-12T10:06:16-04:00November 1st, 2021|Tags: Press Release Tag|

Read More

12 Oct, 2021

Martin Tolar of Alzheon receives the “Czech Laurels Award” from the Chamber of Commerce of the Czech Republic

alzheon2021-10-20T19:25:19-04:00October 12th, 2021|

Read More

13 Sep, 2021

Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021

alzheon2024-08-12T09:32:26-04:00September 13th, 2021|Tags: Press Release Tag|

Read More

13 Sep, 2021

Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development

alzheon2024-08-26T11:01:08-04:00September 13th, 2021|Tags: Press Release Tag|

Read More

7 Sep, 2021

Milepost ALZ-801. Martin Tolar leads one of the greatest Czech successes

alzheon2024-05-14T14:09:19-04:00September 7th, 2021|Tags: Forbes.cz|

Read More